Trial · NCT02075840
Results by group374
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 374
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-Free Survival (PFS) by Investigator Assessment | Alectinib | NA | 95% Confidence Interval 17.7 to NA | months | |
| Progression-Free Survival (PFS) by Investigator Assessment | Crizotinib | 11.1 | 95% Confidence Interval 9.1 to 13.1 | months | |
| Percentage of Participants With PFS Event by Investigator Assessment | Alectinib | 40.8 | Percentage of Participants | ||
| Percentage of Participants With PFS Event by Investigator Assessment | Crizotinib | 67.5 | Percentage of Participants | ||
| PFS Independent Review Committee (IRC)-Assessed | Alectinib | 25.7 | 95% Confidence Interval 19.9 to NA | months | |
| PFS Independent Review Committee (IRC)-Assessed | Crizotinib | 10.4 | 95% Confidence Interval 7.7 to 14.6 | months | |
| Percentage of Participants With PFS Event by IRC | Alectinib | 41.4 | Percentage of Participants | ||
| Percentage of Participants With PFS Event by IRC | Crizotinib | 60.9 | Percentage of Participants | ||
| Percentage of Participants With Central Nervous System (CNS) Progression as Determined by IRC Using RECIST V1.1 Criteria | Alectinib | 11.8 | Percentage of Participants | ||
| Percentage of Participants With Central Nervous System (CNS) Progression as Determined by IRC Using RECIST V1.1 Criteria | Crizotinib | 45.0 | Percentage of Participants | ||
| Percentage of Participants With Central Nervous System (CNS) Progression as Determined by IRC Using Revised Assessment in Neuro Oncology (RANO) Criteria | Alectinib | 10.5 | Percentage of Participants | ||
| Percentage of Participants With Central Nervous System (CNS) Progression as Determined by IRC Using Revised Assessment in Neuro Oncology (RANO) Criteria | Crizotinib | 35.8 | Percentage of Participants | ||
| Percentage of Participants With Objective Response Rate (ORR) of Complete Response (CR) or Partial Response (PR) as Determined by The Investigators According to RECIST V1.1 Criteria | Alectinib | 82.9 | 95% Confidence Interval 75.95 to 88.51 | Percentage of Participants | |
| Percentage of Participants With Objective Response Rate (ORR) of Complete Response (CR) or Partial Response (PR) as Determined by The Investigators According to RECIST V1.1 Criteria | Crizotinib | 75.5 | 95% Confidence Interval 67.84 to 82.12 | Percentage of Participants | |
| Duration of Response (DOR) According to RECIST V1.1 Criteria as Assessed by the Investigators | Alectinib | NA | 95% Confidence Interval NA to NA | Months | |
| Duration of Response (DOR) According to RECIST V1.1 Criteria as Assessed by the Investigators | Crizotinib | 11.1 | 95% Confidence Interval 7.9 to 13.0 | Months | |
| Overall Survival (OS) | Alectinib | NA | 95% Confidence Interval NA to NA | months | |
| Overall Survival (OS) | Crizotinib | NA | 95% Confidence Interval NA to NA | months | |
| Percentage of Participants With OS Event | Alectinib | 23.0 | Percentage of Participants | ||
| Percentage of Participants With OS Event | Crizotinib | 26.5 | Percentage of Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02075840/results